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Of the antiviral agents that are currently in clinical use in the US for therapy for human immunodeflciency virus infections, zalcitabine (ddC) is the most potent and is effective at the lowest plasma concentrations. The two reported procedures for measuring these low concentrations involve a chromatographic technique coupled with mass spectrometry. We have developed a procedure combining solid-phase extraction with a strong cationexchange resin and commercially available RIA reagents for the quantification of ddC in plasma or serum. The method demonstrates good linearity, specificity, and precision,with overall CVs of <10% from 2-20 jhg/L and 17% at 0.8 p.gIL (the lower limit of quantitation). No significant cross-reactivity with nucleoside analogs other than ddC analogs was noted. The major advantages of this assay are its efficiency and relative simplicity, which should facilitate its performance in many laboratories. Zalcitabine is the most potent of the three drugs in cell culture (4) (5) (6) , and is effective clinically at the lowest plasma concentrations.
Indexing Terms:AIDS/drug assay/monitoring therapy/nucleoside analogs
Peak plasma concentrations achieved 1-2 h after administration of a 0.5-mg tablet are -7.5 pg/L (7), and, on the basis of a plasma half-life of -2 h, trough concentrations after the currently recommended dose of 0.75 mg every 8 h should be <1 g/L. These low concentrations make studies requiring plasma concentration measurements difficult. Conventional analytical methods such as HPLC that have proved useful for AZT and ddl analysis lack the requisite sensitivity.
A gas chromatography-mass spectrometry method with a detection limit of 2 gfL has been described (8) but requires multiple derivatization steps and negative chemical ionization.
Recently, an HPLCthermospray mass spectrometry method has been described with a calibration range down to 0.25 jz.gfL (9 
Procedures
Solid-phase extraction. SCX columns were prewashed with 3 mL of methanol followed by 3 mL of water. We diluted aliquots (2 mL) of calibrators, controls, and samples with 2 mL of 2 mol/L phosphoric acid and applied them to the columns on a vacuum manifold. After sample (Meriden, CT), using a spline fit.
RIA validation.
We assessed precision by analyzing four concentrations of ddC (0.8, 2, 10, 20 gfL) in human plasma in quintuplicate on 5 separate days. To assess the linearity of the assay, we pooled the plasma obtained from three patients who were receiving ddC and serially diluted it with drug-free plasma In addition, 1-and 2-mL aliquots of three ddC quality controls (2, 10, and 20 ugfL) were assayed concurrently and the measured concentrations were corrected for the aliquot volume.
We evaluated the specificity of the rabbit antiserum to ddC by measuring the cross-reactivity of antiviral and antimetabolite nucleoside analogs, indudingAZT, ddl, cytosine arabinoside, 5-fluorouracil, acyclovir, gancidovir, and the ddC analogs (+)-and (-)-2',3'-dideoxy-3'-thiacytidine (SddC) and (+)-and
(OddC) pre-pared in aqueous solution. We also prepared ddC standards in pooled serum from patients receiving AZT. The concentration of AZT in the serum pools was quantified with a ZDV-Trac RIA (Incstar Corp., Stifiwater, MN). The analytical recovery of unlabeled ddC from control, lipemic, icteric, and hemolyzed serum specimens was compared with that from plasma.
We determined a pharniacokinetic profile by administering a 0.75-mg dose of ddC to a 95-kg male volunteer and obtaining plasma samples at 0,0. 
Results
We compared the extraction efficiency and reproducibility of 100-and 500-mg SCX columns by using [3H]ddC. Recoveries from the larger columns averaged 89% (n = 3, SD = 1.7%) but were <50% from the smaller ones when 2-mL aliquots of serum or plasma were extracted.
Therefore, the larger columns were used in all subsequent experiments.
The recoveries of [3HIddC from 2-mL aliquots of both serum and plasma were identical, and the presence or absence of 20 ng of unlabeled ddC had no effect. assayed 1-and 2-mL aliquoth of the three highest controls in parallel. The apparent concentrations obtained with the 1-mL aliquots were within 10% of half the value obtained with the 2-mL aliquots.
We assessed the specificity of the RIA reagents in two ways. First, the cross-reactivity of several nudeoside and pyrimidine analogs in aqueous solution was determined without SCX extraction ( g/L), and hyperbilirubinemia (total bilirubin 110 mg/L) had no effect on the recovery of ddC from serum.
A pharmacokinetic profile of ddC concentrations measured when a healthy male volunteer was given a standard 0.75-mg dose of ddC is shown in Fig. 2 
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The stated limit of detection is 3 ±gfL, which is inadequate for measurement beyond 3 h after the currently recommended dosage, and is thus not suit- Several nucleosides that contain cytosine and uracil moieties were previously known to cross-react with ddC antiserum.
Whereas the cross-reactivity of cytidine and 2'-deoxycytidine were 0.01% and 0.12%, respectively, 2',3'-dideoxyuridine, which contains dideoxyribose linked to a pyrimidine base, exhibited 4.1% cross-reactivity on a molar basis (Sigma). However, we found that the cross-reactivity of ddl, which contains dideoxyribose linked to a purine base, was <0.02% and that of d4T, which contains didehydroribose linked to a pyriimdine base, was <0.02% (Table 2) .
Significant cross-reactivity was detected with the ddC analogs (+)-and (-)-SddC (14, 15) and (+)-and (-)-OddC (16), which are candidate antiviral agents for treatment of HW and hepatitis B infections. This suggests that our assay could be adapted to measure these ddC analogs, some of which attain significantly higher plasma concentrations than ddC (17) . The carbon at the 3' position of the dideoxyribose has been replaced with a sulfur atom in the SddC analogs. Since the (+) isomer is in the same conformation as ddC, it is not surprising that substantial cross-reactivity was detected with this compound. The (-) isomer, which is under clinical investigation for the treatment of HW infection, shows 9% cross-reactivity in the ddC RIA. The analogs of these compounds, in which the sulfur atoms have been replaced with oxygen, show less cross-reactivity.
The analog (+)-OddC, which has the same conformation as ddC, shows 4.6% cross-reactivity;
(-)-OddC shows only 0.6%. It is unlikely that the agents mentioned above having substantial cross-reactivity would be administered concurrently with ddC. Cytosine arabinoside, which contains a cytosine moiety but has arabinose in place of dideoxyribose, showed no cross-reactivity with the antibody. The above data suggest that the antibodies to ddC recognize epitopes that include portions of both the cytosine and dideoxyribose moieties. Several other chemotherapeutic agents frequently administered to patients with AIDS showed no cross-reactivity in the assay.
In summary, we have developed an SPE-RIA for ddC that shows excellent linearity and precision for plasma concentrations of the drug that are observed clinically. The commercially available antiserum shows high specificity for ddC and its analogs. The major advantage of this assay over other reported assays is that it can be readily performed in many laboratories.
